SourceMDPI AGInflammatory Signatures of Graves’ Orbitopathy: Linking Thyroid Autoimmunity, Disease Activity, and Novel Hematological Biomarkers
- Publisher
- MDPI AG
- Date
- Jul 7, 2026
- Trust tier
- crossref
- License
- https://creativecommons.org/licenses/by/4.0/
SourceClinicalTrials.govCirculating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer
- Publisher
- ClinicalTrials.gov
- Date
- Jun 25, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govOptimization of Cervical Cancer Screening Among Women Living With HIV in Latin American Countries
- Publisher
- ClinicalTrials.gov
- Date
- Jun 26, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceEuropean Organization for Nuclear ResearchMetaboCovid-19: Metabolomics and Artificial Intelligence for Precision Medicine in COVID-19 Management
- Publisher
- European Organization for Nuclear Research
- Date
- Jul 9, 2026
- Trust tier
- openalex
- License
- cc-by
SourceZaslavsky A.Yu.Autism Spectrum Disorder from Pathophysiology to AI-Driven Precision Medicine A Review
- Publisher
- Zaslavsky A.Yu.
- Date
- Jun 22, 2026
- Trust tier
- openalex
- License
- cc-by
SourceFrontiers MediaHarnessing generative artificial intelligence for periodontitis prediction: a machine learning approach integrating systemic health indicators for precision oral health in resource-limited settings
- Publisher
- Frontiers Media
- Date
- Jun 19, 2026
- Trust tier
- openalex
- License
- cc-by
SourceClinicalTrials.govTesting the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
- Publisher
- ClinicalTrials.gov
- Date
- Jul 10, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govAn Exosomal microRNA Signature for Preoperative Staging in Colon Cancer
- Publisher
- ClinicalTrials.gov
- Date
- Jul 7, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceElsevier BVDiagnostic infrastructuring: Biomarkers, pharmaceutical marketing and governance in Taiwan
- Publisher
- Elsevier BV
- Date
- Jul 9, 2026
- Trust tier
- openalex
- License
- Not specified
SourceClinicalTrials.govTesting the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Publisher
- ClinicalTrials.gov
- Date
- Jul 9, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceMDPI AGNext-Generation Cardiovascular Imaging in Precision Medicine: Integrating Functional Imaging, Artificial Intelligence, Biomarkers, and Personalized Risk Stratification
- Publisher
- MDPI AG
- Date
- Jul 16, 2026
- Trust tier
- crossref
- License
- https://creativecommons.org/licenses/by/4.0/
SourceClinicalTrials.govTesting the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- Publisher
- ClinicalTrials.gov
- Date
- Jun 25, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govActive Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
- Publisher
- ClinicalTrials.gov
- Date
- Jul 16, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceEuropean Organization for Nuclear ResearchPHARMACOLOGY IN THE ERA OF PRECISION MEDICINE: Targeted therapies, Genomics, And Personalized Drug Development
- Publisher
- European Organization for Nuclear Research
- Date
- Jun 20, 2026
- Trust tier
- openalex
- License
- cc-by
SourceNature PortfolioGeneralizable AI predicts immunotherapy outcomes across cancers and treatments
- Publisher
- Nature Portfolio
- Date
- Jul 3, 2026
- Trust tier
- openalex
- License
- cc-by-nc-nd
SourceBioMed CentralEvaluation of squamous cell carcinoma antigen as a diagnostic biomarker in pulmonary diseases: a male cohort study
- Publisher
- BioMed Central
- Date
- Jun 29, 2026
- Trust tier
- openalex
- License
- cc-by-nc-nd
SourceClinicalTrials.govNatural History Study of Patients With Neurofibromatosis Type 2
- Publisher
- ClinicalTrials.gov
- Date
- Jul 17, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceBMJPrecision for all children: embedding equity into precision medicine for children
- Publisher
- BMJ
- Date
- Jul 1, 2026
- Trust tier
- openalex
- License
- cc-by-nc
SourceMDPI AGMultiparametric Abdominal Ultrasound as a Source of Imaging Biomarkers in Predictive and Personalized Medicine: A Narrative Review
- Publisher
- MDPI AG
- Date
- Jun 30, 2026
- Trust tier
- crossref
- License
- https://creativecommons.org/licenses/by/4.0/
SourceClinicalTrials.govEarly Detection of Prostate Cancer
- Publisher
- ClinicalTrials.gov
- Date
- Jun 22, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govcfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer
- Publisher
- ClinicalTrials.gov
- Date
- Jul 7, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govSelf-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)
- Publisher
- ClinicalTrials.gov
- Date
- Jul 7, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceMDPI AGUrinary Extracellular Vesicles Biomarkers in CKD: Clinical Laboratory Translation
- Publisher
- MDPI AG
- Date
- Jul 13, 2026
- Trust tier
- crossref
- License
- https://creativecommons.org/licenses/by/4.0/
SourceBioMed CentralNetwork-based machine learning to identify biomarkers for systemic lupus erythematosus
- Publisher
- BioMed Central
- Date
- Jul 7, 2026
- Trust tier
- openalex
- License
- cc-by-nc-nd
SourceEuropean Organization for Nuclear ResearchPHARMACOLOGY IN THE ERA OF PRECISION MEDICINE: Targeted therapies, Genomics, And Personalized Drug Development
- Publisher
- European Organization for Nuclear Research
- Date
- Jun 20, 2026
- Trust tier
- openalex
- License
- cc-by
SourceMDPI AGPreoperative OCT Biomarkers as Predictors of Postoperative Functional Outcome Assessed by Microperimetry After Inverted ILM Flap Surgery
- Publisher
- MDPI AG
- Date
- Jun 20, 2026
- Trust tier
- crossref
- License
- https://creativecommons.org/licenses/by/4.0/
SourceNature PortfolioAn ECG biomarker for sudden cardiac death discovered with deep learning
- Publisher
- Nature Portfolio
- Date
- Jun 24, 2026
- Trust tier
- openalex
- License
- cc-by
SourceOpenAlex indexed sourceBiomarkers in Personalized Natural Medicine
- Publisher
- OpenAlex indexed source
- Date
- Jun 30, 2026
- Trust tier
- openalex
- License
- Not specified
SourceClinicalTrials.govLung Cancer Organoids and Patient Derived Tumor Xenografts
- Publisher
- ClinicalTrials.gov
- Date
- Jul 13, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceMDPI AGAccuracy and Precision of the Subjective Visual Vertical According to Age in Adults With/Without Diabetes
- Publisher
- MDPI AG
- Date
- Jul 8, 2026
- Trust tier
- crossref
- License
- https://creativecommons.org/licenses/by/4.0/
SourceMultidisciplinary Digital Publishing InstituteThe Programmable Microbiome: Integrative AI and Multi-Omics Frameworks for Precision T2DM Management
- Publisher
- Multidisciplinary Digital Publishing Institute
- Date
- Jun 22, 2026
- Trust tier
- openalex
- License
- cc-by
SourceClinicalTrials.govTesting the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
- Publisher
- ClinicalTrials.gov
- Date
- Jul 16, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govDinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Publisher
- ClinicalTrials.gov
- Date
- Jul 16, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govLiquid Biopsy in Mature B-cell Tumors
- Publisher
- ClinicalTrials.gov
- Date
- Jul 9, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceNeuro-Oncology PediatricsID #397 Diagnostic and predictive molecular biomarkers in brain tumors across the lifespan: an age-stratified consensus statement
- Publisher
- Neuro-Oncology Pediatrics
- Date
- Jun 23, 2026
- Trust tier
- openalex
- License
- cc-by-nc
SourceClinicalTrials.govTesting the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
- Publisher
- ClinicalTrials.gov
- Date
- Jul 1, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceAzad University Cross TeamPlasma and CSF Biomarkers for Early Diagnosis of Alzheimer's Disease: Integrative Multi-Cohort Analysis.
- Publisher
- Azad University Cross Team
- Date
- Jun 19, 2026
- Trust tier
- openalex
- License
- Not specified
SourceCureus, Inc.A Comprehensive Review of the Integration of Biotechnology in Modern Medicine and Pathology: Advances in Diagnostic Techniques, Therapeutic Innovations, and Clinical Outcomes
- Publisher
- Cureus, Inc.
- Date
- Jun 25, 2026
- Trust tier
- openalex
- License
- cc-by
SourceClinicalTrials.govTesting the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
- Publisher
- ClinicalTrials.gov
- Date
- Jul 9, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceCureus, Inc.Artificial Intelligence in Paediatric Allergy: From Diagnostic Support to Precision Medicine
- Publisher
- Cureus, Inc.
- Date
- Jul 15, 2026
- Trust tier
- openalex
- License
- cc-by
SourceClinicalTrials.govExocrine-Endocrine Pancreatic Crosstalk: Precision Pathways to Reframe Diabetes Pathophysiology
- Publisher
- ClinicalTrials.gov
- Date
- Jun 26, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govA Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)
- Publisher
- ClinicalTrials.gov
- Date
- Jul 14, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govPazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
- Publisher
- ClinicalTrials.gov
- Date
- Jul 2, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceMultidisciplinary Digital Publishing InstituteEmerging Biomarkers in Pediatric Food Allergy: From Mechanistic Endotyping to Precision Diagnosis and Therapeutic Monitoring
- Publisher
- Multidisciplinary Digital Publishing Institute
- Date
- Jul 17, 2026
- Trust tier
- openalex
- License
- cc-by
SourcePublic Library of ScienceA scoping review on emerging biomarkers in inflammatory bowel disease: Towards precision medicine in diagnosis and therapeutic management
- Publisher
- Public Library of Science
- Date
- Jul 13, 2026
- Trust tier
- openalex
- License
- cc-by
SourceClinicalTrials.govA Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
- Publisher
- ClinicalTrials.gov
- Date
- Jul 17, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceWileyFrom cytokine storm to renal scarring in diabetic kidney disease: Biomarkers, risk stratification, and precision therapeutics
- Publisher
- Wiley
- Date
- Jun 21, 2026
- Trust tier
- crossref
- License
- http://creativecommons.org/licenses/by/4.0/
SourceWalter de Gruyter GmbHMolecular genetics in laboratory medicine: from foundations to the future of precision diagnostics
- Publisher
- Walter de Gruyter GmbH
- Date
- Jul 7, 2026
- Trust tier
- crossref
- License
- http://creativecommons.org/licenses/by/4.0
SourceClinicalTrials.govNCI COVID-19 in Cancer Patients, NCCAPS Study
- Publisher
- ClinicalTrials.gov
- Date
- Jul 2, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourcePress of International Journal of Ophthalmology (IJO Press)Oculomics: advances and perspectives from traditional Chinese medicine to modern multimodal biomarkers
- Publisher
- Press of International Journal of Ophthalmology (IJO Press)
- Date
- Jul 18, 2026
- Trust tier
- crossref
- License
- Not specified
SourceClinicalTrials.govPROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
- Publisher
- ClinicalTrials.gov
- Date
- Jul 14, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govA Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring
- Publisher
- ClinicalTrials.gov
- Date
- Jul 14, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceCell PressApplication of Epigenetic biomarkers in the precision medicine for sepsis-induced acute lung injury: From risk stratification to targeted therapy
- Publisher
- Cell Press
- Date
- Jul 16, 2026
- Trust tier
- openalex
- License
- cc-by
SourceClinicalTrials.govTesting the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Publisher
- ClinicalTrials.gov
- Date
- Jul 13, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceOpenAlex indexed sourceAdvancing Integrative Health in the Era of Precision and Digital Care
- Publisher
- OpenAlex indexed source
- Date
- Jun 30, 2026
- Trust tier
- openalex
- License
- Not specified
SourceClinicalTrials.govTesting A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
- Publisher
- ClinicalTrials.gov
- Date
- Jul 15, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govMYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Publisher
- ClinicalTrials.gov
- Date
- Jul 13, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceEuropean Organization for Nuclear ResearchIMMUNOMODULATION AND CLINICAL BIOMARKERS: A REVIEW
- Publisher
- European Organization for Nuclear Research
- Date
- Jul 1, 2026
- Trust tier
- openalex
- License
- cc-by
SourceProf. Marin Drinov Publishing House of BAS (Bulgarian Academy of Sciences)Immunohistochemical and Molecular Biomarkers Bridging Pathogenesis and Precision Medicine in Endometrial Carcinoma: A Systematic Review
- Publisher
- Prof. Marin Drinov Publishing House of BAS (Bulgarian Academy of Sciences)
- Date
- Jul 1, 2026
- Trust tier
- crossref
- License
- Not specified
SourceMDPI AGPredicting Chronic Kidney Disease from Biomarkers: An Explainable Machine Learning Approach
- Publisher
- MDPI AG
- Date
- Jun 26, 2026
- Trust tier
- crossref
- License
- https://creativecommons.org/licenses/by/4.0/
SourceClinicalTrials.govTesting Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Publisher
- ClinicalTrials.gov
- Date
- Jul 14, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govSeattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
- Publisher
- ClinicalTrials.gov
- Date
- Jul 1, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govMore Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)
- Publisher
- ClinicalTrials.gov
- Date
- Jul 15, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceMDPI AGPersonalized Protocol for the Dynamic Assessment of Functional Biomarkers of Vascular Stiffness: A Novel Diagnostic Tool in P4 Medicine
- Publisher
- MDPI AG
- Date
- Jun 26, 2026
- Trust tier
- crossref
- License
- https://creativecommons.org/licenses/by/4.0/
SourceClinicalTrials.govAMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
- Publisher
- ClinicalTrials.gov
- Date
- Jul 8, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govMolecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
- Publisher
- ClinicalTrials.gov
- Date
- Jul 15, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govA Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- Publisher
- ClinicalTrials.gov
- Date
- Jun 23, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govTesting the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma
- Publisher
- ClinicalTrials.gov
- Date
- Jul 8, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Publisher
- ClinicalTrials.gov
- Date
- Jul 10, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govMRS of Glioma Genomics
- Publisher
- ClinicalTrials.gov
- Date
- Jul 8, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceMultidisciplinary Digital Publishing InstituteIndividuals with ABO Groups Show Significant Differences in Levels of Circulating Biomarkers Related to Inflammation, Apoptosis, Endothelial Dysfunction, Tissue Remodeling and Neurodegeneration: A Pilot Study
- Publisher
- Multidisciplinary Digital Publishing Institute
- Date
- Jun 19, 2026
- Trust tier
- openalex
- License
- cc-by
SourceClinicalTrials.govGlasgow Low-dose CT and AI-based Diagnostics to Case Find Lung Cancer and Other Cardio-respiratory Long-term Conditions - Feasibility Study
- Publisher
- ClinicalTrials.gov
- Date
- Jun 23, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govCirculating Tumor DNA in Soft Tissue Sarcoma
- Publisher
- ClinicalTrials.gov
- Date
- Jun 23, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govSelf-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)
- Publisher
- ClinicalTrials.gov
- Date
- Jul 7, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govTesting Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma
- Publisher
- ClinicalTrials.gov
- Date
- Jul 8, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govA Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
- Publisher
- ClinicalTrials.gov
- Date
- Jul 10, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceEuropean Organization for Nuclear ResearchIMMUNOMODULATION AND CLINICAL BIOMARKERS: A REVIEW
- Publisher
- European Organization for Nuclear Research
- Date
- Jul 1, 2026
- Trust tier
- openalex
- License
- cc-by
SourceClinicalTrials.govTesting the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
- Publisher
- ClinicalTrials.gov
- Date
- Jul 2, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceElsevier BV132P Precision medicine and systems biology analysis for the identification of PI3K pathway biomarkers and therapeutic candidates in ovarian cancer
- Publisher
- Elsevier BV
- Date
- Jul 1, 2026
- Trust tier
- crossref
- License
- https://www.elsevier.com/tdm/userlicense/1.0/
SourceEuropean Organization for Nuclear ResearchMetaboCovid-19: Metabolomics and Artificial Intelligence for Precision Medicine in COVID-19 Management
- Publisher
- European Organization for Nuclear Research
- Date
- Jul 9, 2026
- Trust tier
- openalex
- License
- cc-by
SourceFrontiers Media SAMultimodal biomarkers in idiopathic sudden sensorineural hearing loss: integrating immune, vascular, and metabolic perspectives for precision medicine
- Publisher
- Frontiers Media SA
- Date
- Jul 10, 2026
- Trust tier
- crossref
- License
- https://creativecommons.org/licenses/by/4.0/
SourceClinicalTrials.govTesting the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
- Publisher
- ClinicalTrials.gov
- Date
- Jul 15, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceElsevier BVInflammation-driven multiorgan Dysfunction: Biomarker-Guided diagnosis, mechanistic insights and emerging precision therapeutic strategies
- Publisher
- Elsevier BV
- Date
- Jun 22, 2026
- Trust tier
- openalex
- License
- cc-by-nc-nd
SourceClinicalTrials.govTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Publisher
- ClinicalTrials.gov
- Date
- Jul 17, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceFrontiers MediaMulti-omics integration in autoimmune encephalitis: from novel biomarker discovery to precision therapeutic strategies
- Publisher
- Frontiers Media
- Date
- Jul 3, 2026
- Trust tier
- openalex
- License
- cc-by
SourceClinicalTrials.govDabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
- Publisher
- ClinicalTrials.gov
- Date
- Jul 10, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govIbrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Publisher
- ClinicalTrials.gov
- Date
- Jul 2, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govTesting MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
- Publisher
- ClinicalTrials.gov
- Date
- Jul 2, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceNature Mental HealthA precision medicine trial of bupropion and sertraline for major depressive disorder using a biomarker-guided sequential multiple-assignment design
- Publisher
- Nature Mental Health
- Date
- Jul 6, 2026
- Trust tier
- openalex
- License
- cc-by
SourceLaboratory ServiceBlood biomarkers in neurodegenerative diseases: pre-analytical, analytical, and post-analytical challenges
- Publisher
- Laboratory Service
- Date
- Jun 29, 2026
- Trust tier
- openalex
- License
- Not specified
SourceClinicalTrials.govSorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
- Publisher
- ClinicalTrials.gov
- Date
- Jun 24, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govTesting the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
- Publisher
- ClinicalTrials.gov
- Date
- Jul 2, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record
SourceClinicalTrials.govLow-Dose CT - Stage I Testicular Cancer
- Publisher
- ClinicalTrials.gov
- Date
- Jun 23, 2026
- Trust tier
- clinical-trials
- License
- ClinicalTrials.gov public registry record